NASDAQ$AMTX

Aemetis Inc · Q4 2024 earnings

Q4 2024 earnings · · Before market open · Investor relations

Briefing

Aemetis reported Q4 2024 revenue of $47.0M, a net loss of $25.4M.

For Q4 2024, Aemetis reported Revenue was $47.0M, net loss was $25.4M. Management discusses segment trends, liquidity, and outlook in the quarterly filing.

  • Revenue $47.0M for Q4 2024.
  • Net loss $25.4M.
  • MD&A highlights operating priorities, liquidity, and sector risks.

Headline financials

Total Revenue

$47M

Previous: $70.8M-33.6%
EPS (adj)

-$0.36

Previous: -$0.64+43.8%
Ethanol Gallons Sold

15.7M

Previous: 15.0M+4.7%
Average Sales Price/Gallon

$1.93

Previous: $2.20-12.3%
Percent of Nameplate Capacity (Ethanol)

114.0%

Previous: 109.0%+4.6%
WDG Tons Sold

105.7K

Previous: 102.6K+3.0%
Average Sales Price/Ton (WDG)

$83.00

Previous: $97.00-14.4%
Bushels Ground (Corn)

5.4M

Previous: 5.2M+3.8%
Average Delivered Cost/Bushel (Corn)

$6.08

Previous: $6.70-9.3%
MMBtu Sold (Renewable Natural Gas)

67.1K

Previous: 52.2K+28.5%
Average Price Per MMBtu

$3.45

Previous: $5.03-31.4%
MMBtu Available to Dispense

24.6K

Previous: 68.0K-63.8%
RINs Sold

987.3K

Previous: 1.1M-12.6%
Average Price Per RIN

$2.70

Previous: $3.30-18.2%
LCFS Credits Sold

8.5K

No prior period
Average Price Per LCFS Credit

$64.80

No prior period
Biodiesel Metric Tons Sold

700

Previous: 18.3K-96.2%
Average Sales Price/Metric Ton (Biodiesel)

$1.23K

Previous: $1.16K+6.1%
Percent of Nameplate Capacity (Biodiesel)

1.8%

Previous: 49.0%-96.3%
Refined Glycerin Metric Tons Sold

1.1K

Previous: 1.3K-15.4%
Average Sales Price/Metric Ton (Glycerin)

$761.00

Previous: $616.00+23.5%
Net Income

-$25.4M

Previous: -$25.4M+0.0%
Operating Income

-$13.5M

Previous: -$9M-49.7%
Gross Profit

-$2.04M

Previous: $864K-336.1%

Revenue & EPS history

Aemetis · Revenue · Quarterly

$47M

Q4 2024-33.6%vs Q4 2023
Beat estimate in 3 of 15 quarters(20%)
ActualEstimate

Revenue by segment

Aemetis · $42.8M total across 1 segment · Q1 2021

  • California Ethanol
    $42.8M+74.8%

Forward guidance

Outlook emphasizes clinical milestones, liquidity runway, and operating expense discipline.

Tailwinds

  • Pipeline progress and partnership economics.
  • Cash supports near-term operating plans.

Headwinds

  • Operating losses until commercial scale.
  • Financing and trial outcomes affect funding costs.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

-3.5%

Avg return

Earnings day

-3.2%

Avg return

5 days after

-2.6%

Avg return

30 days after

32%

20 / 62 earnings

Positive

+29.3%

Q4 2020

Best reaction

-37.5%

Q2 2010

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-4.0%-30.2%-30.6%
Q4 2025+25.5%+77.3%+47.4%
Q3 2025-13.2%+4.9%-26.2%
Q1 2025+7.1%+16.2%+50.0%
Q4 2024-6.1%+11.3%-9.3%
Q3 2024+15.0%+6.7%-15.0%
Q2 2024-22.4%-17.8%-23.4%
Q1 2024-3.4%-1.4%-25.1%
Q4 2023+1.2%-3.0%+57.2%
Q3 2023-1.3%+0.2%-0.7%
Q2 2023+9.5%+4.8%-28.3%
Q1 2023-13.8%-11.1%+126.7%
Q4 2022-23.6%-21.3%-42.1%
Q3 2022-0.6%-7.6%-19.3%
Q2 2022+29.2%+29.1%+6.7%
Q1 2022+9.3%+17.1%+4.3%
Q4 2021-7.2%-27.1%-18.6%
Q3 2021+3.3%-4.0%-14.9%
Q2 2021+4.0%-6.0%+40.4%
Q1 2021-27.5%-18.2%+13.8%
Q4 2020+29.3%+14.3%+62.0%
Q3 2020-36.7%-36.1%-35.5%
Q2 2020-26.6%-8.4%-36.2%
Q1 2020+6.9%+11.4%+15.0%
Q4 2019-8.1%-30.9%-15.5%
Q3 2019-2.9%-7.8%-1.9%
Q2 2019-4.1%-6.3%-17.3%
Q1 2019-14.6%-10.8%-32.3%
Q4 2018-0.3%-5.9%-7.1%
Q3 2018-4.0%-5.9%-25.6%
Q2 2018-8.1%-7.4%-10.3%
Q1 2018-0.5%-2.7%-20.7%
Q4 2017-21.5%-17.0%-11.0%
Q3 2017-3.9%-8.9%-12.6%
Q2 2017+2.6%+0.7%-21.1%
Q1 2017-8.8%-11.6%+6.1%
Q4 2016-0.8%+0.0%+0.7%
Q3 2016+11.8%+0.6%+0.2%
Q2 2016+0.0%-12.4%-30.6%
Q1 2016+6.2%
Q4 2015-5.6%
Q3 2015+2.3%
Q2 2015-1.5%
Q1 2015-8.0%
Q4 2014-9.4%
Q3 2014-14.3%
Q2 2014-14.7%
Q1 2014+23.7%
Q4 2013+10.5%
Q3 2013-20.0%
Q2 2013-7.4%
Q1 2013-6.1%
Q4 2012-6.1%
Q3 2011-5.8%
Q2 2012-12.5%
Q3 2012-12.5%
Q2 2011+12.5%
Q1 2011-7.7%
Q4 2010+7.1%
Q3 2010+1.0%
Q2 2010-37.5%
Q1 2010+0.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro